In-PharmaTechnologist.com reports its periodic round-up of new appointments in the pharmaceutical sector, headlined this week by the appointment of a new head of manufacturing at US drugmaker Merck & Co.
Willie Deese, currently senior vice president of global procurement at Merck & Co, has been named president of the group's manufacturing division, succeeding Richard Clark who has been elected chief executive of the firm following the recently announced resignation of Raymond Gilmartin.
Rolf Krebs will join the board of E Merck OHG on 1 July, replacing Peter Zuhlsdorff who will vacate his position - at his own request - as of the same date. Until the end of 2003, Krebs was chairman of German drugmaker Boehringer Ingelheim. Merck OHG handles the financial interests of the Merck family and is general partner of Germany pharmaceutical and chemical firm Merck KGaA, holding a 73 per cent interest.
Frankfurt, Germany-based engineering company Lurgi has appointed Klaus Moll as its new executive chairman, with effect from 1 June. He is already a member of the board at Lurgi's parent company mg technologies, with responsibility for the plant engineering segment. Moll will succeed Michael Stratling at Lurgi, and the latter will join the supervisory board of the firm.
Pierre Kerjouan has become head of legal affairs at French pharmaceutical company Sanofi-Aventis, following the resignation of Dirk Oldenburg. Meanwhile, just over 500 Sanofi-Aventis employees aged over 55 have accepted a proposal from the management that they leave the company in return for a guaranteed 70 per cent of net salary up to their legal retirement age.
The US subsidiary of Japanese drugmaker Eisai has appointed Lyn Olson as vice president of quality at the company's pharmaceutical production and formulation research and development facility in Research Triangle Park, North Carolina. In her role, Dr Olson will oversee all aspects of quality control and quality assurance. She joins Eisai from Protein Design Laboratories, where she served as vice president of quality and regulatory compliance.
Cambrex has named David Bethune to its board of directors, effective immediately. He was previously chairman and chief executive of Atrix Laboratories, having also held these roles at generics firm IVAX Laboratories.
James Posada has been appointed to the newly created position of senior vice president of business and market development at GlycoFi, which specialises in making drugs in yeast cells. He will report directly to Sylvie Gregoire, GlycoFi's CEO.
Linguagen, which develops new compounds to improve the taste of pharmaceutical, food and beverage products, has named Bernd Nilius to its scientific advisory board. Dr Nilius is an expert in the biology of cell signaling through ion channels.
US drug major Schering-Plough has promoted Michael Perelman to the position of vice president, global project management, at its Schering-Plough Research Institute, based at Kenilworth, New Jersey.
One of Pharmaceutical Profiles' founders, Ian Wilding is to be honoured at this year's Controlled Release Society Annual Meeting held later this month in Florida, US, with a major career achievement award. He will receive the 2005 Career Achievement in Oral Drug Delivery Award, sponsored by the CRS and Eurand.